Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

248 - Aurora Kinase A (AURKA) is an independent predictor of recurrence in breast ductal carcinoma in situ (DCIS)

Date

05 Mar 2018

Session

Poster display

Presenters

Islam Miligy

Citation

Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047

Authors

I.M. Miligy1, A. Gaber2, M.S. Toss1, A. Hamad1, C. Nolan1, M. Diez-Rodriguez1, I.O. Ellis1, A. Green1, E. Rakha3

Author affiliations

  • 1 Academic Pathology, Nottingham University Hospitals NHS Trust-City Hospital Campus, NG5 1PB - Nottingham/GB
  • 2 Faculty of Medicine - Menoufia University, Shebin El Kom/EG
  • 3 Nottingham University Hospitals NHS Trust-City Hospital Campus, Nottingham/GB
More

Resources

Abstract 248

Current clinical and pathological parameters are important predictors of recurrence in breast ductal carcinoma in situ (DCIS) but they are insufficient to reflect its molecular heterogeneity. Biological characterisation has the potential for individualising therapy for DCIS. Aurora Kinase A (AURKA), located on 20q13.2, shows copy number alteration in DCIS and is a key regulator of cell cycle progression. High expression of AURKA is associated with poor outcome in invasive breast cancer (IBC), however it is not confirmed in the pre-invasive stage. This study aims to assess the role of AURKA in DCIS behaviour.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings